On Mar. 13, 2024, the Fred Hutchinson Cancer Center announced that a blood test intended for screening for colorectal cancer in people who are of average risk and not experiencing symptoms correctly detected colorectal cancer in 83% of people confirmed to have the disease. The study was published in the New England Journal of Medicine.

The accuracy rate for colorectal cancer is similar to at-home stool tests used for early detection of colorectal cancer. The findings come from the ECLIPSE study, a multisite clinical trial of nearly 8,000 people ages 45 to 84 led and funded by Guardant Health.